Immune to Cancer: The CRI Blog
-
Celebrating 71 Years of Immunotherapy Successes
January 27, 2024, marks CRI’s 71st anniversary as an institution, and specifically as an organization focused solely… -
Exploring the Different Types of Cancer and Treatment Options
Cancer is a formidable adversary, but our understanding of this disease has come a long way. Cancer… -
Unraveling the Pro-Tumorigenic Myelopoiesis Driven by an IL-4 Signaling Axis in Bone Marrow
CRI is delighted to share the latest milestone achievement from CRI-supported investigators at Icahn School of Medicine… -
CRI Immunologists Are Armed Against Lung Cancer, the Most Common Cancer Worldwide
A Large Cancer Presence on a Global Scale The Cancer Research Institute (CRI) has a singular focus:… -
How CRI is Taking on Pancreatic Cancer, “The Silent Killer”
Immunotherapy holds the greatest promise for optimizing outcomes for cancer patients, and eventually finding a cure for… -
This is How CRI Funded Scientists are Fighting Breast Cancer
A Global Challenge Breast cancer poses a formidable challenge to healthcare, being one of the most common… -
Prostate Cancer: A Unique and Common Cancer Affecting Men
Most cancers affect everyone, regardless of sex, race, age, and other factors. Prostate cancer, however, only affects… -
Dr. Jill O’Donnell-Tormey on the State of Cancer Immunotherapy and the Contributions CRI Continues to Make to the Field
iFrame is not supported! Recently, the Cancer Research Institute’s (CRI) CEO and Director of Scientific Affairs Jill… -
Dr. Jill O’Donnell-Tormey Discusses the Latest Developments in Immunological Technologies
CRI’s CEO and Director of Scientific Affairs, Dr. Jill O’Donnell-Tormey, recently spoke with ecancer about recent developments…